将以下内容翻译为英文恶性肿瘤是危害人类健康和生命的重要疾病其发病率和致死率一直居高不下。分子影像在肿瘤等重大疾病的早期诊断、分期、预后评价以及疗效评估中发挥着重要作用。目前临床应用最广泛的分子影像是18F-FDG的PET显像但仍存在生理性摄取、假阴性、假阳性等问题亟需探讨及转化一种新型肿瘤靶向PET成像。 整合素是细胞黏附分子家族的重要成员有24种亚型与肿瘤转移及侵袭密切相关已成为肿瘤靶向成

Malignant tumors are a significant disease that threatens human health and life, with high incidence and mortality rates. Molecular imaging plays an important role in the early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment of major diseases such as tumors. Currently, 18F-FDG PET imaging is the most widely used molecular imaging, but there are still problems such as physiological uptake, false negatives, and false positives. It is urgent to explore and develop a new type of tumor-targeting PET imaging.

Integrin is an important member of the cell adhesion molecule family, with 24 subtypes, which is closely related to tumor metastasis and invasion and has become a popular target for tumor-targeted imaging. In the past 20 years, PET imaging probes have mostly targeted the αvβ3 subtype of integrin, but this type of probe has no direct relationship with angiogenesis activity or density, and because αvβ3 is widely expressed in normal endothelial cells, the imaging background interference level is high in multiple organs. Unlike the expression of αvβ3, αvβ6 can only be expressed in epithelial cells that undergo cancerous transformation or tissue reconstruction, and is almost not expressed in healthy epithelial cells, with better expression specificity, hence αvβ6 is also known as "cancer integrin". Recently, a new PET probe targeting integrin αvβ6, 68Ga-Trivehexin, has been successfully developed internationally in 2021, with significantly better tumor affinity and selectivity than other similar probes, and can effectively distinguish malignant tumors from inflammatory lesions.

The safety and metabolic stability of 68Ga-Trivehexin targeting integrin αvβ6 are currently supported by clinical data, and this project will further expand its application in various malignant tumors, clarify its diagnostic and staging value in different types of tumors, and qualitative and quantitative characteristics, and compare it head-to-head with 18F-FDG. This project is expected to provide a new and precise evaluation method for malignant tumors to compensate for the shortcomings of current imaging methods.